Literature DB >> 22337897

Pharmacokinetic mismatch of tuberculosis drugs.

Charles A Peloquin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22337897      PMCID： PMC3294955          DOI： 10.1128/AAC.06303-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.

Authors:  Marc Weiner; William Burman; Andrew Vernon; Debra Benator; Charles A Peloquin; Awal Khan; Stephen Weis; Barbara King; Nina Shah; Thomas Hodge
Journal:  Am J Respir Crit Care Med       Date:  2003-01-16       Impact factor: 21.405

2.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

3.  Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.

Authors:  A Vernon; W Burman; D Benator; A Khan; L Bozeman
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

4.  Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Authors:  Marc Weiner; Debra Benator; William Burman; Charles A Peloquin; Awal Khan; Andrew Vernon; Brenda Jones; Claudia Silva-Trigo; Zhen Zhao; Thomas Hodge
Journal:  Clin Infect Dis       Date:  2005-04-14       Impact factor: 9.079

5.  Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.

Authors:  Shashikant Srivastava; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

6.  Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.

Authors:  William Burman; Debra Benator; Andrew Vernon; Awal Khan; Brenda Jones; Claudia Silva; Chris Lahart; Stephen Weis; Barbara King; Bonita Mangura; Marc Weiner; Wafaa El-Sadr
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

7.  Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.

Authors:  Amina Jindani; Caroline J Doré; Denis A Mitchison
Journal:  Am J Respir Crit Care Med       Date:  2003-01-06       Impact factor: 21.405

8.  Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1981-04

9.  Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.

Authors:  Catherine Boulanger; Elena Hollender; Karen Farrell; Jerry Jean Stambaugh; Diane Maasen; David Ashkin; Stephen Symes; Luis A Espinoza; Rafael O Rivero; Jenny J Graham; Charles A Peloquin
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079
  9 in total
  1 in total

1.  TB and HIV Therapeutics: Pharmacology Research Priorities.

Authors:  Kelly E Dooley; Peter S Kim; Sharon D Williams; Richard Hafner
Journal:  AIDS Res Treat       Date:  2012-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.